Blood Pressure Drugs Cut Heart Risk Only With Steady Doses

Blood pressure drugs cut major heart events by 11% only when patients took at least 80% of doses, an Oxford analysis of 91,339 people found. Below that line, the same treatment produced no clear drop in stroke, heart attack, or heart-failure crises.

Qianqian Yang, a second-year DPhil student at the University of Oxford, presented the pooled results on 30 August 2026 at the European Society of Cardiology Congress in Munich.

The 11% Cut Showed Up in One Group Only

Yang’s team worked inside the Blood Pressure Lowering Treatment Trialists’ Collaboration, which holds individual records from more than 360,000 participants from 52 major trials. Professor Kazem Rahimi chairs that group at Oxford, with Dr Milad Nazarzadeh. The British Heart Foundation funded the adherence project (FS/19/36/34346).

The new analysis pulled patient-level data from nine randomised trials in which a blood pressure regimen was compared with placebo or a lighter plan. People who took at least 80% of their assigned treatment were classed as higher adherence. Those under 80% were classed as lower adherence. The 80% mark was updated at each follow-up visit, so a person could move bands as the years passed.

A wider overlay of 12 trials covered 115,389 people, 15,460 major cardiovascular events, and 9,591 deaths over a median 4.7 years. The adherence split that drives the headline result sits in the nine trials with longitudinal dose records.

Yang said earlier links between missed doses and worse outcomes came from observational studies that can mix in other habits. The point of using randomised trial files was to compare the assigned treatment with the control inside each adherence band, rather than to compare diligent patients with people who skip pills.

That design still cannot make missed doses themselves random. People who stop taking tablets may also skip clinic visits or change diet. What the pooling can show is whether the extra treatment still beat the comparator among those who stayed on it, and among those who did not.

What the 80% Line Did to Heart Risk

Systolic pressure, the first number in a reading, fell more when people stayed on therapy. In the higher-adherence band, the intervention lowered systolic pressure by 5.2 mmHg (5.0 to 5.4) versus the comparator. In the lower-adherence band, the gap was 3.0 mmHg (2.7 to 3.3). The difference between those effects had a P for interaction under 0.001. That is a 2.2 mmHg extra drop when doses were kept.

BLOOD PRESSURE AND HEART EVENTS BY ADHERENCE

Major cardiovascular disease here meant stroke, myocardial infarction or ischemic heart disease, and heart failure that caused death or a hospital stay. Treatment cut those events by 11% in the higher-adherence band (hazard ratio 0.89). In the lower-adherence band the hazard ratio was 1.01 (0.92 to 1.10), which is no significant reductions in patients with lower adherence. The treatment-by-adherence interaction for events had a P value of 0.04.

A 3.0 mmHg systolic shift is not zero. Across a large population, small average drops can still move event counts. In this split, the event analysis did not follow that leftover pressure change. The 11% sits with the people who cleared the 80% line.

Notably, our results reinforce the saying that ‘drugs don’t work in patients who don’t take them.’ Patients with lower adherence derived little or no cardiovascular benefit, whereas those with higher adherence had greater reductions in blood pressure and prevention of cardiovascular events.

Qianqian Yang, DPhil student, University of Oxford, ESC Congress 2026

Trial Patients Drifted Off the Pills Anyway

These were not casual clinic lists. Trial volunteers get free drugs, scheduled visits, and reminders. Even there, the share classed as higher adherence fell from 88% in year one to 79% by year five, a 9-point slide. Yang said a decline was apparent in that structured setting.

Mean adherence, a slightly different measure, fell in both arms. It went from 88% to 80% in the intervention groups and from 87% to 77% in the comparator groups by year five. The habit eroded whether the assigned pills were the intensive plan or the control.

High blood pressure often gives no warning. WHO notes that most people with hypertension feel nothing until vessels and organs are already under strain. Side effects, cost, stacked daily schedules, and doubt about whether a quiet condition needs a lifelong tablet all make skipping easy. The trial data put a number on what that skip costs in heart events, even before real-world chaos is added.

If 21% of closely watched trial patients were already below the 80% line by year five, a routine pharmacy queue will sit lower still. The brochure 11% is the high-adherence edition of a therapy that a large share of patients never actually receive.

Adding Another Tablet Can Hide the Real Problem

When a reading stays high, the common next step is another class of drug. That move treats a high number as a potency problem. A 2017 review led by Tadesse Melaku Abegaz looked at 12,603 adults in 25 studies and found 45.2% were not taking their blood pressure drugs as directed. Among people whose pressure was still uncontrolled, 83.7% were nonadherent.

Before a clinic adds a fourth tablet because the cuff is still high, the Oxford split argues for a simpler question: whether the third tablet is being taken. More complexity is a poor fix for missed doses, because each extra bottle is another chance to skip.

CHECKS THAT PROTECT THE 11%

• Missed doses: Ask, without blame, how many days were skipped before the dose is raised.
• Once-daily drugs: Prefer long-acting tablets so an occasional missed day leaves less of a gap.
• One combination pill: Fold two or three classes into a single tablet when the mix is already needed.
• A time that sticks: Tie the dose to a daily habit the patient already keeps.
• Cost and side effects: Treat both as reasons people stop, not as footnotes after a new script.

Yang’s group listed the same toolkit: simpler regimens, single-pill combinations to cut the bottle count, and longer-acting agents whose effect holds better when a day is missed. None of that requires a new molecule. It requires treating the blister pack as part of the diagnosis.

Guidelines Already Prefer One Combination Pill

This is not a new sermon. The 2024 ESC document on elevated blood pressure already says combination treatment should start for most people with confirmed hypertension at 140/90 mmHg or higher, usually a renin-angiotensin blocker with a calcium-channel blocker or a diuretic. In patients who are already on a combination, fixed-dose single-pill combination treatment is recommended as a Class I, Level B item.

The same guideline says adherence in ordinary practice is almost always lower than in trials, and that most apparent treatment-resistant hypertension is accounted for by non-adherence. It also says tablets should be taken at the most convenient time of day, so the dose becomes a habit (Class I, Level B). Objective checks, including witnessed intake or drug levels in blood or urine, are reserved mainly for suspected resistance.

Professor Felix Mahfoud, chair of the ESC Communication Committee, still described missed doses as a neglected cause of uncontrolled pressure. The textbooks already list the problem. The Munich numbers are about what clinics actually do when the cuff stays high.

For years, we have neglected non-adherence to medication as a cause for uncontrolled hypertension. Assessment of adherence should become a routine part of hypertension care so patients do not miss out on life-saving benefits. As healthcare providers, we are here to have open, non-judgemental conversations with our patients about any barriers they may have to taking medication, to help improve adherence.

Professor Felix Mahfoud, Chair, ESC Communication Committee, ESC Congress 2026

1.4 Billion People, and Most Are Not at Target

WHO’s 2025 hypertension report estimates 1.4 billion adults aged 30 to 79 had high blood pressure in 2024, 33% of that age band. The count was 650 million in 1990. Two-thirds of those adults live in low- and middle-income countries. Only just over one in five have it under control.

THE GLOBAL HYPERTENSION CASCADE IN 2024

• Unaware: 600 million adults (44%) do not know they have high blood pressure.
• Treated: 630 million adults (44%) are diagnosed and on treatment.
• Controlled: 320 million adults (23%) have readings in range.
• Deaths: Uncontrolled high blood pressure claims more than 10 million lives a year, more than 1000 an hour from related strokes and heart attacks, per WHO Director-General Dr Tedros Adhanom Ghebreyesus.

Control rates sit under 20% in 99 of 195 countries. Only 7 of 25 low-income countries (28%) report that all WHO-recommended blood pressure medicines are generally on the shelf, against 93% of high-income countries. Where the bottle is missing, adherence is a later problem. Where the bottle is in the house and the cuff is still high, the Oxford split says the next fact to collect is how many doses were actually taken.

WHO’s HEARTS package has put 13.5 million people in more than 40 low- and middle-income countries on protocol-based treatment since 2017. South Korea reached 59% national control in 2022 after low drug prices and capped patient fees. Those programmes work when the pills are present, cheap, and simple enough to keep.

The 11% cut is real for people who stay on therapy. The same files show that even trial patients drift, and that below 80% of doses the event benefit was not there. Yang’s group says the next job is to make that check routine, and to make the regimen easy enough that year five still looks like year one.

Frequently Asked Questions

How Much of a Blood Pressure Prescription Do You Need to Take for Heart Protection?

The Oxford team used 80% of assigned doses as the cutoff and recoded that yes-or-no mark at every follow-up visit, rather than averaging one figure for the whole study. That 80% line is a research rule of thumb, not a personal target your clinician has to copy, and a full journal paper could still revise the exact cut.

What Blood Pressure Reading Is Used to Diagnose Hypertension?

WHO defines clinical hypertension in adults as a systolic reading of 140 mmHg or higher and/or a diastolic reading of 90 mmHg or higher, confirmed on two different days. Many people are still treated toward a goal under 140/90, and under 130/80 if they already have heart disease, diabetes, chronic kidney disease, or high cardiovascular risk.

What Is the Difference Between Adherence and Persistence?

The 2024 ESC guideline defines adherence as how far a patient’s behaviour, including pill-taking, matches agreed advice from a clinician. Persistence is the time from the first dose to the day the therapy is stopped. A person can persist for years and still miss enough days to fall under the 80% line used in the Munich analysis.

Which Medicines Are Commonly Used to Lower Blood Pressure?

WHO lists ACE inhibitors such as enalapril and lisinopril, angiotensin-2 receptor blockers such as losartan and telmisartan, calcium-channel blockers such as amlodipine and felodipine, and diuretics such as hydrochlorothiazide and chlorthalidone. Combination tablets pair two of those classes so the daily count of bottles falls.

Disclaimer: This article is news reporting on a conference analysis and on World Health Organization figures. It is informational only and is not medical advice, a diagnosis, or a recommendation to start, stop, or change any blood pressure medicine. Speak with a qualified physician or cardiologist before altering treatment, doses, or schedules. The figures and study status reflect the ESC Congress 2026 presentation and the WHO publications named above and may change if a full peer-reviewed paper or later global estimates are issued.